CorMedix Inc. (CRMD)
| Market Cap | 593.70M |
| Revenue (ttm) | 311.71M |
| Net Income (ttm) | 162.07M |
| Shares Out | 78.43M |
| EPS (ttm) | 2.04 |
| PE Ratio | 3.71 |
| Forward PE | 13.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,221,655 |
| Open | 7.89 |
| Previous Close | 7.82 |
| Day's Range | 7.54 - 7.98 |
| 52-Week Range | 6.13 - 17.43 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 14.83 (+95.91%) |
| Earnings Date | May 11, 2026 |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $14.83, which is an increase of 95.91% from the latest price.
News
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline results from the Phase 3 ReSPECT trial assessing REZZAYO (rezafungin) for the prophylaxis of invasive...
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is expanding its institutional pharmaceutical portfolio following the Melinta acquisition, with REZZAYO's phase III prophylaxis data expected soon and DefenCath navigating a temporary reimbursement dip before a 2027 rebound. Pipeline growth includes a TPN indication, and financials remain strong with a $75M buyback program.
CorMedix to Participate in Needham Virtual Healthcare Conference
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni...
CorMedix Transcript: The Citizens Life Sciences Conference 2026
REZZAYO's phase III prophylaxis data is expected later in Q2, targeting a $2B+ TAM in transplant patients. DefenCath's launch is strong, with Medicare Advantage seen as a major growth driver, and the Melinta acquisition has stabilized revenue. Operational scaling will follow key clinical milestones.
CorMedix Transcript: Leerink Global Healthcare Conference 2026
The company has evolved into a diversified specialty pharma, expanding its institutional care portfolio and advancing key assets like REZZAYO and DefenCath. Strong clinical results, strategic reimbursement efforts, and a robust financial position support growth, with multiple catalysts expected in the next 12–18 months.
CorMedix stock drops after earnings: is this dip a buy before key catalyst?
CorMedix (NASDAQ: CRMD) opened meaningfully down on March 5th after reporting a massive swing to profitability but reaffirming 2026 guidance that failed to impress shareholders. The biopharmaceutical ...
CorMedix Earnings Call Transcript: Q4 2025
2025 saw record revenue growth and the Melinta acquisition, with strong Q4 results and robust cash flow. 2026 guidance is affirmed, though price erosion is expected post-TDAPA, and new product catalysts are anticipated. Active share repurchases and a strong pipeline support long-term growth.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Sched...
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr...
CorMedix to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Transcript: Investor Day 2026
The company has transformed into a diversified specialty pharma platform, achieving record sales and integrating Melinta to expand its anti-infective portfolio. Rezzayo and DefenCath are positioned for significant growth in high-risk patient populations, with strong clinical and payer support, and multiple late-stage trials underway to address large unmet needs.
CorMedix Therapeutics Announces Share Repurchase Program
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record 2025 revenue was driven by DefenCath and Melinta, with 2026 guidance reflecting a transitional reimbursement period. Growth is expected from Rezzayo’s phase 3 readout, DefenCath’s TPN expansion, and strategic business development, supported by strong cash and IP positions.
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
Why is CorMedix stock crashing today: is it worth buying on the dip?
Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn't sitting well with shareholders, prima...
CorMedix Therapeutics Announces Leadership and Board Updates
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 mi...
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of...
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.
CorMedix Earnings Call Transcript: Q3 2025
Record Q3 2025 results driven by DefenCath and Melinta acquisition, with net revenue of $104.3M and net income of $108.6M. Raised full-year guidance and expect strong cash generation, while advancing late-stage pipeline and integration synergies.
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance R...
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...